Literature DB >> 12687806

Beneficial effects of biventricular pacing in patients with a "narrow" QRS.

Maurizio Gasparini1, Massimo Mantica, Paola Galimberti, Manuel Marconi, Luca Genovese, Francesco Faletra, Stefano Simonini, Catherine Klersy, Robert Coates, Edoardo Gronda.   

Abstract

Congestive heart failure (CHF) patients with LBBB and QRS duration > 150 ms are considered the best candidates to biventricular pacing (Biv-P). However, patients with a narrow (120-150 ms) QRS may also benefit from Biv-P since true ventricular dyssynchrony may be underestimated by considering only QRS enlargement. From October 1999 to April 2002, 158 CHF patients (121 men, mean age 65 years, mean LVEF 0.29, mean QRS width 174 ms) underwent successful Biv-P implantation and were then followed for a mean time of 11.2 months. According to basal QRS duration, patients were divided in two groups, with wide QRS (> or = 150 ms, 128 patients, 81%) and with narrow QRS (< 150 ms, 30 patients, 19%). In the wide QRS group, LVEF improved from 29% to 39% (P < 0.0001), 6-minute walk test from 311 to 463 m (P < 0.0001), while NYHA Class III-IV patients decreased from 86% to 8% (P < 0.0001). In the narrow QRS group LVEF improved from 30% to 38% (P < 0.0001), 6-minute walk test from 370 to 506 m (P < 0.0001), and NYHA Class III-IV patients decreased from 60% to 0% (P < 0.0001). The data showed that in wide and narrow QRS patients, Biv-P significantly improved clinical parameters (NYHA class, 6-minute walk test, quality-of-life, and hospitalization rate) and main echocardiographic indicators. Furthermore, narrow QRS patients had a better survival rate, rapidly regained left ventricular function, and only a few patients remained in a higher NYHA class during follow-up. These patients should not be excluded "a priori" from cardiac resynchronization therapy.

Entities:  

Mesh:

Year:  2003        PMID: 12687806     DOI: 10.1046/j.1460-9592.2003.00010.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  9 in total

Review 1.  Heart failure overview.

Authors:  Dennis V Cokkinos; Basil S Lewis
Journal:  Heart Fail Rev       Date:  2006-06       Impact factor: 4.214

2.  Relationship between mechanical and electrical remodelling in patients with cardiac resynchronization implanted defibrillators.

Authors:  Nicolas Lellouche; Carlos De Diego; Noel G Boyle; Isaac Wiener; Gina Akopyan; John S Child; Kalyanam Shivkumar
Journal:  Europace       Date:  2011-04-12       Impact factor: 5.214

3.  [Indication for cardiac resynchronization therapy: Consensus 2005].

Authors:  C W Israel; C Butter
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006

Review 4.  Selection and optimisation of biventricular pacing: the role of echocardiography.

Authors:  R E Lane; A W C Chow; D Chin; J Mayet
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

Review 5.  Cardiac resynchronization therapy guided by cardiovascular magnetic resonance.

Authors:  Francisco Leyva
Journal:  J Cardiovasc Magn Reson       Date:  2010-11-09       Impact factor: 5.364

6.  Cross-correlation delay to quantify myocardial dyssynchrony from phase contrast magnetic resonance (PCMR) velocity data.

Authors:  Jana G Delfino; Brandon K Fornwalt; Robert L Eisner; Angel R Leon; John N Oshinski
Journal:  J Magn Reson Imaging       Date:  2008-11       Impact factor: 4.813

Review 7.  Cardiac resynchronisation therapy in heart failure: current status.

Authors:  J Claude Daubert; Christophe Leclercq; Erwan Donal; Philippe Mabo
Journal:  Heart Fail Rev       Date:  2006-06       Impact factor: 4.654

8.  Cardiac resynchronization therapy in heart failure: recent advances and new insights.

Authors:  V Bhatia; R Bhatia; S Dhindsa; A Virk
Journal:  Indian Pacing Electrophysiol J       Date:  2003-07-01

9.  Multipoint Pacing versus conventional ICD in Patients with a Narrow QRS complex (MPP Narrow QRS trial): study protocol for a pilot randomized controlled trial.

Authors:  Maurizio Gasparini; Paola Galimberti; Renato Bragato; Stefano Ghio; Claudia Raineri; Maurizio Landolina; Enrico Chieffo; Maurizio Lunati; Ederina Mulargia; Alessandro Proclemer; Domenico Facchin; Roberto Rordorf; Alessandro Vicentini; Lina Marcantoni; Francesco Zanon; Catherine Klersy
Journal:  Trials       Date:  2016-12-03       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.